Consumers can check the FDA's website for a full list of recalled drugs. No contaminants have been found in Novartis' Diovan, the brand-drug version of valsartan, according to the FDA. Throughout ...

Attorney: 3 to 5 million consumers affected. The FDA said valsartan made with contaminated ingredients may have gone undetected for up to four years. The FDA announced the first recall in July ...

Sacubitril/valsartan was associated with reduced natriuretic peptides and lower risk for CV death and HF hospitalization across the spectrum of ejection fraction, particularly in those with EF ...

Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/320 mg/25 mg, 30-count bottles, lot. Nos. 22x045, 22x046 and 22x047, expiration 2/2019.

These products — with the active ingredient valsartan, a generic drug used to treat high blood pressure — may contain N-nitrosodimethylamine (NDMA), a possible human carcinogen.

FDA expands recall on blood pressure drug valsartan due to probable carcinogen 02:42. Online pharmacy Valisure has discovered another cancer-causing chemical in blood-pressure pills made by ...

Mylan expands nationwide recall for blood pressure medication 01:17. Pharmaceutical firm Mylan is dramatically expanding a nationwide recall of some blood pressure medications after detecting ...

A Danish study finds that recalled blood pressure and heart failure drugs containing tainted valsartan were not linked with a significant increase in overall cancer risk, in the short term. More ...

With blood pressure patients on edge after numerous recalls of valsartan, losartan and irbesartan for too much NDEA, FDA commissioner Scott Gottlieb and Center for Drug Evaluation and Research ...

It said FDA scientists estimate that if 8,000 people took the highest valsartan dose (320 mg) from the recalled batches every day for the full four years, there may be one additional case of ...

Sacubitril/valsartan reduced the rate of the primary endpoint by 13% (rate ratio, 0.87; 95% CI, 0.75 - 1.01; P = .06). There were 894 primary endpoint events in the sacubitril/valsartan arm ...